Severity
Critical
FDA Drug recall · Reported September 4, 2013
Marketed Without An Approved NDA/ANDA: FDA analysis found this product contained undeclared sibutramine and phenolphthalein, two active ingredients that were once marketed in the …
Bethel Nutritional Consulting, Inc recalled Bethel 30 capsules, packaged in 30 count bottles, Distributed by BETHEL INC. New York, Ne… - a critical-severity action.
Bethel 30 capsules, packaged in 30 count bottles, Distributed by BETHEL INC. New York, Ne… was recalled by Bethel Nutritional Consulting, Inc in September 4, 2013. Reason: Marketed Without An Approved NDA/ANDA: FDA analysis found this product contained undeclared sibutramine and p…. Check the official notice for the remedy. Verify recall #D-921-2013 with the FDA Drug before acting.
The recall
Bethel Nutritional Consulting, Inc issued this critical-severity FDA Drug recall-Marketed Without An Approved NDA/ANDA: FDA analysis found this product contained undeclared sibutramine and p….
Sourced from official FDA Drug enforcement records. Verify recall #D-921-2013 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-921-2013) was formally reported on September 4, 2013, with the manufacturer initiating the action on June 11, 2013. It is classified under Critical severity (Class I), with a current status of Terminated. Bethel Nutritional Consulting, Inc is listed as the recalling firm, operating out of New York, NY. Federal records list the affected scope as 18,678 bottles.
The documented reason for this recall is: Marketed Without An Approved NDA/ANDA: FDA analysis found this product contained undeclared sibutramine and phenolphthalein, two active ingredients that were once marketed in the U.S. but removed due to safety reasons, … Distribution data in the federal record shows the product reached: Nationwide. Product was also available for sale via internet. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Critical
Affected scope
18,678 bottles
Related Recalls
6
5 from same agency
Bethel 30 capsules, packaged in 30 count bottles, Distributed by BETHEL INC. New York, New York
Marketed Without An Approved NDA/ANDA: FDA analysis found this product contained undeclared sibutramine and phenolphthalein, two active ingredients that were once marketed in the U.S. but removed due to safety reasons, making this product an unapproved new drug.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Critical (Class I) |
| Status | Terminated |
| Recall number | D-921-2013 |
| Date reported | September 4, 2013 |
| Date initiated | June 11, 2013 |
| Recalling firm | Bethel Nutritional Consulting, Inc |
| Firm location | New York, NY |
| Affected scope | 18,678 bottles |
| Distribution | Nationwide. Product was also available for sale via internet |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported September 4, 2013. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.